Introduction
Natural antibodies refer to any type of immunoglobulin present in the serum of an individual in the absence of deliberate immunization or infection. These antibodies can be of the IgM, IgG or IgA isotypes (Lacroix-Desmazes et al., 1998) , and recognize several self and foreign antigens in mice (Baccala et al., 1989; Guilbert et al., 1982; Haury et al., 1994) . Natural auto-antibodies also occur in healthy humans, as well as in patients with autoimmune disease, where they react with a wide range of evolutionary conserved cell surface, intracellular and circulating antigens including DNA, thyroglobulin, senescent cell antigens, and constant and variable regions of immunoglobulin and the T cell antigen receptor (TCR) (Lacroix-Desmazes et al., 1998) . However, the precise role of natural antibodies in physiological and pathological immunity remains unclear.
Experimental autoimmune encephalomyelitis (EAE) is a neuroinflammatory disease in which anti-myelin CD4 + T helper (Th) cells have a key contribution by recruiting and stimulating peripheral macrophages and resident microglia, which are the ultimate responsible for demyelination, oligodendrocyte death and axonal dysfunction (Merrill et al., 1992) . EAE is a surrogate model of human multiple sclerosis (MS) that has contributed to understand the mechanisms underlying the disease and its potential treatment (Steinman and Zamvil, 2005) . In EAE as well as in MS, the anti-myelin CD4 + T cells responsible for disease development express an oligoclonal Vβ TCR repertoire (Acha-Orbea et al., 1988; Kotzin et al., 1991; Oksenberg et al., 1993; Padula et al., 1991; Urban et al., 1988; Zaller et al., 1990) . During EAE, animals develop both T-cell (Kumar and Sercarz, 1993) and humoral (Hashim et al., 1990; Hashim et al., 1991) immune responses against the TCR of encephalitogenic T cells; and these T cells and antibodies protected from EAE when passively transferred into naïve mice. The mechanisms of action of regulatory anti-TCR T cells have been analyzed extensively and may involve anergy (Kumar et al., 1995) , deletion (Madakamutil et al., 2003) or immune deviation of the cytokine response (Kumar and Sercarz, 1998) of encephalitogenic T cells. In contrast, although the role of induced anti-TCR antibodies in regulating encephalitogenic T cells has been addressed in some studies (Aroeira, 2006; Hashim et al., 1990; Zhou and Whitaker, 1993) , the precise mechanisms underlying their regulatory properties remain to be clearly defined. Natural anti-TCR antibodies are present in the serum of healthy mice and humans (Marchalonis et al., 1994) , and at higher levels in patients with rheumatoid arthritis, systemic lupus erythematosus (Marchalonis et al., 1992) and myasthenia gravis (Jambou et al., 2003) . Some natural anti-TCR monoclonal antibodies have been generated and characterized (Marchalonis et al., 1994; Robey et al., 2000) . However, their therapeutic potential remains to be determined. In the present study, we tested the capability of a novel natural anti-TCRVβ8 monoclonal antibody to protect against autoimmune encephalomyelitis, and characterized its effects on the T-cell response during disease development.
Materials and methods

Mice
Six-to eight-week-old female B10.PL and SJL mice were used in the experiments. Encephalitogenic T cells in B10.PL mice use mainly Vβ8.2 (Acha-Orbea et al., 1988) while SJL mice, which were used as control, have their Vβ8 genes deleted (Behlke et al., 1986) and their encephalitogenic T cells bear Vβ17a and Vβ4 (Padula et al., 1991) . B10.PL and SJL mice were obtained from Instituto de Ciências Biomédicas of Universidade de São Paulo, Brasil, and CEMIB (Campinas, São Paulo), respectively. The study was approved by the institutional ethical board for animal studies.
EAE induction
For EAE induction, 200 μg of guinea pig myelin basic protein (MBP; Sigma-Aldrich, St. Louis, MO) in 100 μl of PBS was emulsified in an equal volume of complete Freund's adjuvant (CFA; Life Technologies, Paisley, UK) supplemented with 400 μg BCG (Instituto Butantã, São Paulo; SP), and injected subcutaneously into the base of the tail on day 0. Mice also received 200 ng of pertussis toxin (Life Technologies) intravenously on days 0 and 2. Clinical symptoms were monitored daily after immunization. The clinical score was graded as follows: 0, no disease; 1, tail limpness; 2, hind limb weakness; 3, hind limb paralysis; 4, fore limb weakness; and 5, quadriplegia or death.
C1-19 preparation and treatment
C1-19 is a monoclonal IgM/k antibody obtained by fusion of spleen cells from a normal non-immunized BALB/c mouse with the nonsecreting P3X63Ag8.653 myeloma line. C1-19 was selected based on its ability to recognize recombinant Vβ8.2 in ELISA and stain the TCRVβ8-expressing Yac-1 cell line in flow cytometric assays. For further analysis of antibody specificity, primary spleen cells from a B cell-deficient (B6μmt) mouse (Kitamura et al., 1991) were used to avoid nonspecific staining by endogenous antibodies. The C1-19-secreting hybridoma was cultured in RPMI 1640 (Life Technologies) containing 7% B6μmt mouse serum. IgM concentration in the culture supernatant was determined by standard ELISA. For antibody treatment, culture supernatant containing 10 μg of C1-19 or control irrelevant IgM immunoglobulin (Southern Biotechnology, Birmingham, AL, USA) diluted in RPMI plus 7% B6μmt mouse serum were injected i.p. every other day, starting at day 4 after MBP immunization, or when first signs of disease were detected (mice showing clinical score 1).
Proliferation assay
Spleen cells (5 × 10 6 ) were cultured for 72 h at 100 μl/well with 50 μg/ml of MBP in RPMI 1640 supplemented with 5% FCS, 50 μM 2-ME, 100 μg streptomycin and 100 U/ml of penicillin, all from Life Technologies. Cultures were pulsed with 0. (cpm) using a liquid scintillation β-counter.
FACS staining and analysis
For two-color surface staining, 1 × 10 6 cells in 30 μl PBS with 0.5% BSA (Life Technologies) were incubated with each monoclonal antibody on ice for 20 min. Staining was performed with saturating concentrations of the following fluorescein isothiocyanate (FITC) and biotin-conjugated monoclonal antibodies (BD Biosciences, San Diego, CA, USA): anti-CD3, anti-CD4, anti-CD8, anti-CD45RB, anti-CD69, anti-TCRVβ3, anti-TCRVβ8 and anti-TCRVβ9. Phycoerythrin-conjugated streptavidin (BD Biosciences) was used to detect biotinylated antibodies. For intracellular cytokine staining, cells were cultured in the presence of Golgi transport inhibitor for the final 4 h of culture. Cells were then surface-stained with anti-CD4-PerCP, followed by fixation and permeabilization using Cytofix/Cytoperm (BD Biosciences) according to the manufacturer's protocol. Finally, cells were stained with anti-IFN-γ-FITC and anti-IL-4-PE and analyzed by flow cytometry.
Cytokine assays
IFN-γ and IL-4 in culture supernatants were measured by ELISA using purified and biotinylated antibody pairs, standards and streptavidin-HRP according to the manufacturer (BD Biosciences); and o-phenylene-diamine (Sigma-Aldrich) as substrate. Concentrations were calculated on the basis of standard curves using recombinant IFN-γ and IL-4.
Statistical analysis
Statistical analysis was performed using the Mann-Whitney nonparametric test. P values less than 0.05 were considered statistically significant.
Results
C1-19 recognizes TCRVβ8 on mouse primary T cells
C1-19 is a monoclonal IgM antibody generated by hybridoma technology using spleen cells from a non-immunized BALB/c mouse. C1-19 was selected on the basis of its reactivity for recombinant TCRVβ8 and the TCRVβ8 + Yac-1 cell line in ELISA and flow cytometry assays, respectively (data not shown). To determine whether C1-19 was also able to recognize TCRVβ8 on the surface of primary T cells, we performed three-color staining of spleen cells from B6μmt mice using a combination of anti-TCRCβ (H57-597), anti-TCR Vβ8.1 and Vβ8.2 (MR5-2) and C1-19 monoclonal antibodies. C1-19 stained a fraction of splenic TCRCβ + cells (Fig. 1A) which were also positive for staining with the anti-TCRVβ8 antibody MR5-2 (Fig. 1B) , while TCRCβ + C1-19 − T cells were not stained by MR5-2. Moreover, the analysis of C1-19 and MR5-2 staining of TCRCβ + spleen cells showed that all T cells stained by MR5-2 were also reactive with C1-19 (Fig. 1C) , indicating further that C1-19 recognizes TCRVβ8, and that C1-19 and MR5-2 bind to non-overlapping epitopes on TCRVβ8.
Together, these data demonstrate that C1-19 is an anti-TCRVβ8 antibody capable of detecting this particular TCRVβ element on the surface of primary mouse T cells. (Table 1) . Together, these data indicate that C1-19 acts in vivo as a non-deleting but activating antibody for TCRVβ8 + T cells.
Next, we examined the capability of C1-19 to induce T-cell activation in vitro compared with F23.1, a non-natural anti-TCRVβ8 monoclonal (IgG2a) antibody (Staerz et al., 1985) . For this, we stimulated splenocytes with immobilized (plastic-adsorbed) C1-19 or F23.1 antibodies. C1-19 was less effective than F23.1 for induction of cell size increase ( Fig. 2A) and surface upregulation of the early activation markers CD69 (Fig. 2B ) and CD25 (Fig. 2C) . Furthermore, C1-19 was a poor inducer of IFN-γ even when used at ten-fold the amount of F23.1 (Fig. 2D ), while provoking a slight but consistent increase in the frequency of activated T cells expressing IL-4. Thus, compared with the non-natural F23.1 antibody, C1-19 is a weaker inducer of early T-cell activation.
C1-19 prevents EAE induction in B10.PL but not SJL mice
We next evaluated the effect of C1-19 on the development of EAE induced by MBP immunization in B10.PL mice, in which encephalitogenic T cells are mainly TCRVβ8 + (Acha-Orbea et al., 1988), or SJL mice that have all the Vβ8 gene family deleted and their encephalitogenic T cells use preferentially Vβ17a and Vβ4 (Padula et al., 1991) . Mice were immunized with MBP in CFA (day 0), and subsequently treated with low-dose C1-19 or vehicle every other day from day 4. In another group of B10.PL mice, C1-19 treatment was started at the onset of disease (mice showing clinical score 1). As shown in Fig. 3 , both B10.PL and SJL mice developed EAE in response to MBP immunization. Strikingly, treatment with C1-19 completely prevented the establishment of EAE in B10.PL, but not in SJL mice. Furthermore, C1-19 reduced the clinical score of and prevented disease progression when administered after the first signs of disease ( Fig. 3 ; upper panel). These results demonstrate that continuous low-dose administration of C1-19 can prevent EAE specifically in mice in which disease is mediated by anti-MBP TCRVβ8 + T cells, such as B10.PL.
In addition, C1-19 could partially treat ongoing EAE in B10.PL mice, significantly reducing the worsening of disease when administered after the appearance of the first clinical signs (Table 2) .
C1-19-mediated protection from EAE is independent from deletion or anergy, but correlates with deviation of the cytokine response of MBP-reactive T cells
To confirm that the protective effect of C1-19 on EAE establishment was not dependent on deletion of TCRVβ8 + cells, we determined the frequency of these cells in B10.PL mice treated or not with C1-19. On day 10 after EAE induction, the frequency of CD4 Thus, similarly to non-immunized mice (Table 1) , C1-19 does not seem to cause major deletion of TCRVβ8 + T cells in mice developing EAE.
Next, we tested the effect of C1-19 on the in vitro recall response to MBP. For this, B10.PL and SJL splenocytes were harvested on day 10 after EAE induction, and re-stimulated in vitro with MBP for assessment of proliferation and cytokine responses. T cells from C1-19-treated B10.PL and SJL mice exhibited MBP-induced proliferation comparable to that of splenocytes from untreated mice (Fig. 4B) , indicating that MBP-reactive T cells in mice treated with C1-19 are not anergic. In contrast to this, secretion of the signature Th2 cytokine, IL-4, in response to antigen was significantly augmented by C1-19 in B10.PL but not SJL mice (Fig. 4C, left) . Curiously, MBP-induced production of IFN-γ, a signature Th1 cytokine, was not affected by C1-19 treatment in either B10.PL or SJL mice (Fig. 4C, right) . Collectively, these results indicate that C1-19-mediated protection is independent from deletion or anergy of MBP-specific T cells, but could be a consequence of deviation of the MBP-specific response towards a Th2-like cytokine profile.
Interruption of C1-19 treatment results in attenuated EAE
Since C1-19 did not cause deletion or anergy of MBP-specific T cells during EAE, we were prompted to evaluate the effect of interrupting C1-19 treatment on the course of the disease. Treatment of B10.PL with C1-19 was started on day 4 and discontinued on day 20. Five days after stopping C1-19 administration, three out of five mice developed disease but with reduced clinical scores compared to untreated animals ( Fig. 5) , suggesting a residual therapeutic action of C1-19 treatment. Thus, C1-19-mediated protection against EAE seems to be dependent on immune regulatory mechanisms requiring the continuous presence of the antibody.
Discussion
In the present study, we evaluated the therapeutic potential of a novel natural anti-TCRVβ8 antibody, named C1-19, in the prevention and treatment of autoimmune neuroinflammation. C1-19 is an IgM antibody and because this isotype is a strong complement activator, C1-19 could therefore be potentially cytolytic for TCRVβ8 + T cells. C1-19 prevented EAE in B10.PL but not in SJL mice, which indicates that the regulatory actions of the antibody result from interaction with T cells bearing the TCR involved in the anti-MBP response, i.e. TCRVβ8, and not from nonspecific effects of administrating IgM immunoglobulin. Apart from preventing EAE induction, C1-19 also displayed therapeutic potential, reducing the severity of EAE when provided upon disease onset. CD4 + Th cells are the main contributors to the pathogenic mechanisms responsible for the onset and progression of autoimmune diseases. CD4 + T-cell infiltration of the central nervous system is required for the development of autoimmune encephalomyelitis, with infiltrating macrophages and resident microglia acting as the ultimate effectors causing demyelination, oligodendrocyte death and loss of axonal function (Merrill et al., 1992) . Activation of macrophages and microglia depends critically on pro-inflammatory Th1 cytokines, such as IFN-γ, thus explaining the essential role of Th1 cells in the initiation and establishment of the neurological disease (Jee and Matsumoto, 2001; Kuchroo et al., 1993; Willenborg et al., 1999) . Recently, it was demonstrated that IL-17-secreting T (Th17) cells also play a critical role in the development of EAE (Langrish et al., 2005) . On the contrary, Th2/Th3 cytokines such as IL-4, IL-10 and TGF-β have a preventive effect on EAE (Racke et al., 1994) . These regulatory cytokines antagonize pro-inflammatory cytokines, in particular IFN-γ, by reducing their expression or suppressing their effects (Murphy and Reiner, 2002; O'Shea and Paul) . Therefore, the deviation of the anti-MBP response towards an IL-4-dominated Th2-like cytokine profile could, at least partly, explain the beneficial effects of C1-19 in the prevention and/or amelioration of EAE (Tran et al., 2001) . Although the precise molecular mechanisms underlying the protective effects of C1-19 in EAE remain to be further determined, our results clearly indicate that C1-19, in contrast to previously reported non-natural antibodies against constant or variable regions of TCR components (Kohm et al., 2005; Lavasani et al., 2007; Zaller et al., 1990 ) acts through mechanisms not involving down-modulation of surface TCR, deletion or unresponsiveness of antigen-specific T cells. Yet, the immune regulatory mechanisms and therapeutic effect triggered by C1-19 seemed to require the continuous presence of the antibody, at least at the dose and administration protocol tested in the study. This latter feature could be partly related to the use of a relatively low dosage of the antibody, compared with previous studies with nonnatural anti-TCR antibodies (Acha-Orbea et al., 1988; Urban et al., 1988; Zaller et al., 1990) . Alternatively, the higher clearance rate for IgM compared to IgG antibodies could be underlying the need for continued administration of C1-19. Interestingly, mice treated with C1-19 presented as FCS-containing culture supernatant developed a strong IgE response against bovine albumin, ultimately leading to anaphylactic shock (Stark-Aroeira, unpublished data). Because IgE responses are Th2-dependent (Romagnani, 2000; Yazdanbakhsh et al., 2001) , the latter finding further supports that C1-19 specifically induces immune deviation of antigen-specific T cells towards a Th2-like cytokine profile (Falcone and Bloom, 1997) , an effect that could be secondary to sub-optimal induction of TCR cross-linking and signaling by C1-19 (Leitenberg and Bottomly, 1999; Nakayama and Yamashita) . This latter property of C1-19 could in turn be associated with the intrinsic low affinity of natural antibodies and/or a more restricted cellular expression of FcRs for IgM (Boes, 2000) compared to their counterparts for IgG. Importantly, due to their intrinsic low affinity, natural antibodies are unlikely to induce the strong release of pro-inflammatory cytokines which results in what is known as "first dose" syndrome (Alegre et al., 1990; Ferran et al., 1990) , an undesirable side-effect restricting the use of anti-TCR antibodies as therapeutic agents.
In conclusion, our study demonstrates that C1-19, a natural anti-TCR monoclonal antibody, can protect against autoimmune encephalomyelitis by, at least partly, skewing the global response to selfantigen in a Th2 direction and independently from T-cell deletion or anergy. Thus, C1-19 could be a useful tool in mouse models of pathology for understanding the immune regulatory properties of natural anti-TCR antibodies (Boes, 2000; Marchalonis et al., 2002) . Furthermore, our study establishes a proof-of-concept for a therapeutic value of natural anti-TCR antibodies and for development of natural antibody-based therapies (Holmoy and Vartdal, 2007; Vollmers and Brandlein, 2005; Zhang et al., 2003) applicable in human autoimmune inflammatory diseases (Adelman et al., 2007; Jambou et al., 2003; Schluter et al., 2003) .
